Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting
Research output: Contribution to journal › Conference article › Research › peer-review
Standard
Methotrexate Use and Monitoring in Patients with Psoriasis : A Consensus Report Based on a Danish Expert Meeting. / Raaby, Line; Zachariae, Claus; Østensen, Monika; Heickendorff, Lene; Thielsen, Peter; Grønbæk, Henning; Skov, Lone; Kyvsgaard, Nini; Madsen, Jakob T; Heidenheim, Michael; Funding, Anne T; Strauss, Gitte; Lindberg, Rune; Iversen, Lars.
In: Acta Dermatovenereologica, Vol. 97, No. 4, 2017, p. 426-432.Research output: Contribution to journal › Conference article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - GEN
T1 - Methotrexate Use and Monitoring in Patients with Psoriasis
T2 - A Consensus Report Based on a Danish Expert Meeting
AU - Raaby, Line
AU - Zachariae, Claus
AU - Østensen, Monika
AU - Heickendorff, Lene
AU - Thielsen, Peter
AU - Grønbæk, Henning
AU - Skov, Lone
AU - Kyvsgaard, Nini
AU - Madsen, Jakob T
AU - Heidenheim, Michael
AU - Funding, Anne T
AU - Strauss, Gitte
AU - Lindberg, Rune
AU - Iversen, Lars
PY - 2017
Y1 - 2017
N2 - Methotrexate (MTX) has been used in the treatment of psoriasis and other dermatological diseases for more than 50 years. However, there is limited evidence regarding its effect, dose and monitoring, and a lack of consensus regarding how the drug should be used in daily practice. Although the use of MTX is governed by guidelines, such as the European S3-Guidelines and the National Institute for Health and Care Excellence (NICE) guideline, it is important to discuss and adjust these guidelines to national standards. An expert meeting was held in Denmark at the end of 2014, in order to reach consensus regarding the use of MTX in dermatological practice in Denmark. Participants included dermatologists, hepatologists, paediatricians, clinical biochemists and a rheumatologist. Topics discussed were: liver disease monitoring, teratogenic effects of MTX, risk of cancer, and use of MTX in children. We report here the conclusions of this expert meeting regarding use of MTX in dermatological practice.
AB - Methotrexate (MTX) has been used in the treatment of psoriasis and other dermatological diseases for more than 50 years. However, there is limited evidence regarding its effect, dose and monitoring, and a lack of consensus regarding how the drug should be used in daily practice. Although the use of MTX is governed by guidelines, such as the European S3-Guidelines and the National Institute for Health and Care Excellence (NICE) guideline, it is important to discuss and adjust these guidelines to national standards. An expert meeting was held in Denmark at the end of 2014, in order to reach consensus regarding the use of MTX in dermatological practice in Denmark. Participants included dermatologists, hepatologists, paediatricians, clinical biochemists and a rheumatologist. Topics discussed were: liver disease monitoring, teratogenic effects of MTX, risk of cancer, and use of MTX in children. We report here the conclusions of this expert meeting regarding use of MTX in dermatological practice.
U2 - 10.2340/00015555-2599
DO - 10.2340/00015555-2599
M3 - Conference article
C2 - 27958611
VL - 97
SP - 426
EP - 432
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
SN - 0001-5555
IS - 4
ER -
ID: 173675142